Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients

[1]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[2]  H. Chan,et al.  Predictors of Treatment Response in Chronic Hepatitis B , 2009, Drugs.

[3]  P. Komolmit,et al.  Comparison between quantitative hepatitis B surface antigen, hepatitis B e‐antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon‐α‐2b therapy in hepatitis B e‐antigen‐positive chronic hepatitis B , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  E. Steyerberg,et al.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.

[5]  L. Demelia,et al.  A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B , 2009, Antiviral therapy.

[6]  P. Komolmit,et al.  Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  T. Asselah,et al.  High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. , 2009, Journal of hepatology.

[8]  P. Marcellin,et al.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.

[9]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[10]  P. Marcellin,et al.  Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.

[11]  F. Ansaldi,et al.  Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis. , 2009, Hepato-gastroenterology.

[12]  V. Wong,et al.  A review of the natural history of chronic hepatitis B in the era of transient elastography , 2008, Antiviral therapy.

[13]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[14]  K. Simon,et al.  Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.

[15]  Y. Liaw,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update , 2008, Hepatology international.

[16]  K. Yuen,et al.  96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. , 2008, Journal of hepatology.

[17]  G. Lau,et al.  Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B , 2008, Hepatology international.

[18]  R. Gish,et al.  A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B , 2007, The American Journal of Gastroenterology.

[19]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[20]  Olga Angelopoulou,et al.  Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels , 2007, Antiviral therapy.

[21]  F. Sanai,et al.  Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia. , 2006, World journal of gastroenterology.

[22]  H. Janssen,et al.  Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine , 2006, The American Journal of Gastroenterology.

[23]  D. Blondin,et al.  Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D , 2005, Gut.

[24]  D. Blondin,et al.  Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. , 2005, Gut.

[25]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[26]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[27]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[28]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[29]  J. Rodés,et al.  Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. , 2002, Gastroenterology.

[30]  S. Hadziyannis,et al.  The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .

[31]  S. Hadziyannis,et al.  The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. , 2001, Journal of hepatology.

[32]  M. Brunetto,et al.  Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. , 1995, Journal of hepatology.

[33]  M. Brunetto,et al.  Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. , 1993, Gastroenterology.

[34]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[35]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[36]  M. Milella,et al.  Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. , 1992, Journal of hepatology.

[37]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[38]  E. Schiff,et al.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.

[39]  A. Makris,et al.  Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.